Form 4: Fractyl Health Exec Granted 845K Stock Options

Fractyl Health's President and Chief Product Officer, Jay David Caplan, was granted 845,226 stock options with an exercise price of $2.24, vesting over three years.

Summary

• Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC. (GUTS), reported the acquisition of derivative securities.
• The transaction involved a stock option (right to buy) for 845,226 shares of common stock.
• The exercise price for these stock options is $2.24 per share.
• The options were granted on December 15, 2025, which is also the earliest transaction date reported.
• These stock options vest in equal installments on each of the first three anniversaries of the grant date, contingent on Mr. Caplan's continued employment.
• The expiration date for these derivative securities is December 14, 2035.
• Following this transaction, Mr. Caplan beneficially owns 845,226 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event (stock option grant). This is generally positive as it aligns executive interests with shareholders, but it does not reflect operational performance or new strategic developments, hence a moderately positive score.

Positives

• The grant of stock options aligns the interests of a key executive, Jay David Caplan, with those of shareholders, as the options gain value if the company's stock price increases.
• The long vesting schedule (three years) encourages long-term commitment and performance from the President and Chief Product Officer.

Future Outlook

The vesting schedule of the stock options over the next three years indicates an expectation of continued employment and contribution from the President and Chief Product Officer, aligning executive incentives with future company performance.

Industry Context

The grant of stock options to a senior executive is a common practice in the biotechnology and healthcare industry, serving as a key component of executive compensation packages designed to attract, retain, and motivate talent by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• The structure of this stock option grant, including a multi-year vesting schedule, is consistent with standard executive compensation practices observed across publicly traded companies in the biotechnology sector, such as Moderna, BioNTech, or Vertex Pharmaceuticals, where long-term incentives are crucial for retaining key scientific and leadership talent.
• The exercise price of $2.24, likely the market price on the grant date, is typical for at-the-money options granted to executives, similar to grants seen at emerging growth companies in the health tech space.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can be viewed positively as it aligns management's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: This compensation structure may signal stability in executive leadership and a commitment to long-term growth, which can positively influence employee morale and retention.

Next Steps

• The stock options will vest in equal installments on the first, second, and third anniversaries of the grant date (December 15, 2025), subject to continued employment.

Key Dates

Keywords

FRACTYL HEALTH, GUTS, Stock Option, Executive Compensation, Insider Transaction, Form 4, Derivative Securities, Jay David Caplan